Magnetic resonance imaging using gadolinium labeled monoclonal antibody

Area of Science:

• Biomedical Imaging
• Radiochemistry
• Immunology

Background:

• Gadolinium (Gd) chelates are essential for Magnetic Resonance Imaging (MRI) contrast.
• Antibodies offer targeted delivery, but their use as contrast agents requires efficient Gd conjugation.
• Diethylenetriaminepentaacetic acid (DTPA) is a common chelating agent for Gd.

Purpose of the Study:

• To evaluate the efficacy of gadolinium-DTPA-conjugated antibodies as MRI contrast agents.
• To determine the feasibility of using monoclonal antibodies for targeted in vivo MRI contrast enhancement.
• To assess the required Gd concentrations for proton relaxation enhancement in vitro and in vivo.

Main Methods:

• Conjugation of DTPA to albumin, IgG, and anti-CEA monoclonal antibody using the cyclic anhydride method.
• Chelation of gadolinium (Gd) to the protein-DTPA complexes.
• In vitro assessment of proton relaxation enhancement at 0.35 tesla.
• In vivo evaluation in hamsters with human colon carcinoma xenografts.

Main Results:

• Successful attachment of Gd to proteins, with varying efficiencies (e.g., ~1.5 Gd atoms per monoclonal antibody).
• In vitro proton relaxation enhancement observed at 10(-1) mM Gd concentration (IgG-DTPA-Gd).
• In vivo tumor Gd concentration was below 10(-4) mM, insufficient for detectable contrast enhancement.

Conclusions:

• Current methods for attaching Gd to monoclonal antibodies result in low concentrations in vivo.
• Significant technological advancements are needed to enable selective MR contrast enhancement using antibody-based agents.
• Further research is required to optimize Gd loading and targeting for effective antibody-based MRI contrast agents.